

Hygeia Solutions

PO Box 80626 ~ Baton Rouge, LA 70898 ~ www.hygeia.fyi

Public policy in pharmacy practice

Regular Session of the 2025 Louisiana Legislature
Convened 04-14-2025 @ 12 Noon – Adjourned 06-12-2025 @ 6:00 p.m.

Final Legislative Report ~ 07-07-2025

Last Items Reviewed						
HB 696	HR 383	HCR 83	HSR 1	HCSR 1		
SB 248	SR 211	SCR 70	SSR 2	SCSR 0	Acts 516	
Total = 1,695					Items on Watch List = 29	

House of Representatives

Bills

HB 12 L. Schlegel [R-82, Metairie] Administration of Criminal Justice
Provides relative to the sale of consumable hemp products. (08-01-2025)

02-21-2025 Prefiled and referred to committee.
04-23-2025 Amended, then reported favorably.
04-24-2025 Engrossed; passed to 3rd reading and House floor vote.
04-30-2025 Amended, then passed House (97-0); reengrossed;
Sent to the Senate.
05-05-2025 Received in the Senate; committee referral pending.
05-06-2025 Referred to the Senate Committee on Judiciary-C.
05-13-2025 Amended, then reported favorably.
05-19-2025 Referred to the Legislative Bureau.
05-20-2025 Reported without Legislative Bureau amendments;
Passed to 3rd reading and final passage.
05-28-2025 Called for debate; returned to the calendar, subject to call.
06-03-2025 Called for debate; amended, then passed Senate (37-0);
Returned to the House.
06-04-2025 Received in the House with Senate amendments;
Pending House concurrence with Senate amendments.
06-08-2025 House concurred with Senate amendments (95-0).
06-09-2025 Enrolled; signed by House Speaker & Senate President;
Sent to the Governor.
06-11-2025 Signed by Governor as **Act No. 233**; effective 08-01-2025.

This bill amended the controlled substance law as well as the consumable hemp product law. With respect to the controlled substance law, the bill amended the existing exemption for consumable hemp products as well as the existing criminal penalties for illegal acts with Schedule I substances. House Committee Amendment No. 592 made technical changes to correct drafting errors relative to legal citations. House Floor

[Amendment No. 2059](#) inserted an exception to the criminal penalties for licensed processors, wholesalers and retailers acting in good faith. [Senate Committee Amendment No. 1505](#) corrected an error in House Floor Amendment No. 2059 relative to entities acting in good faith.

[HB 15](#) S. Mack [R-95, Livingston] Administration of Criminal Justice
Adds certain substances to the Uniform Controlled Dangerous Substances Law. (08-01-2025)

02-25-2025 Prefiled and referred to committee.
05-07-2025 Reported favorably.
05-08-2025 Engrossed; passed to 3rd reading and House floor vote.
05-13-2025 Passed House (96-0); sent to the Senate.
05-14-2025 Received in the Senate; committee referral pending.
05-19-2025 Referred to the Senate Committee on the Judiciary-C.
05-28-2025 Reported favorably.
05-29-2025 Referred to the Legislative Bureau.
06-01-2025 Reported without Legislative Bureau amendments;
 Passed to 3rd reading and final passage.
06-02-2025 Passed Senate (39-0); returned to the House;
 Received in the House without Senate amendments.
06-03-2025 Enrolled; signed by House Speaker.
06-04-2025 Signed by Senate President.
06-05-2025 Sent to the Governor.
06-08-2025 Signed by Governor as **Act No. 121**; effective 08-01-2025.

[Sponsored by the Board of Pharmacy and State Police Crime Lab, this bill amended the controlled substance law by adding two opiates and one stimulant to Schedule I.](#)

[HB 99](#) B. Billings [R-56], Destrehan House & Governmental Affairs
Provides relative to adjudications and judicial review of adjudications. (gov. sig.)

03-24-2025 Prefiled and referred to committee.
04-29-2025 Amended, then reported favorably.
04-30-2025 Engrossed; passed to 3rd reading and House floor vote.
05-06-2025 Called for debate; returned to the calendar, subject to call;
 Notice given.
05-07-2025 Passed House (70-27); sent to the Senate.
05-08-2025 Received in the Senate; committee referral pending.
05-12-2025 Referred to the Senate Committee on Senate & Governmental
 Affairs.
05-21-2025 Reported favorably.
05-27-2025 Referred to Legislative Bureau.
05-28-2025 Reported without Legislative Bureau amendments;
 Passed to 3rd reading and final passage.
05-29-2025 Passed Senate (28-10); returned to the House.
06-02-2025 Received from the Senate without amendments;
 Enrolled; signed by House Speaker & Senate President.
06-03-2025 Sent to the Governor.
06-08-2025 Signed by Governor as **Act No. 139**; effective 06-08-2025.

This bill amended the administrative procedure law, and more specifically the subsection relative to adjudications by state agencies. Previous law provided a right to respondents to seek judicial review of an adverse adjudication by a state agency. This bill further provides that during such judicial review, the judge or hearing officer shall not defer to the agency's interpretation of the statute or rule, but instead, shall personally interpret the relevant statute or rule. Further, any remaining doubt shall be granted to a reasonable interpretation which limits agency power and maximizes individual liberty. [House Committee Amendment No. 1190](#) repeals the previous prohibition against an agency seeking judicial review, added language that prohibits an agency from seeking judicial review of a final order if the agency issued the final order, and made other technical changes.

[HB 112](#) K. Edmonston [R-88], Gonzales Health & Welfare
Provides relative to the prescribing, administering, and dispensing of drugs for off-label use. (08-01-2025)

03-25-2025 Prefiled and referred to committee.
05-07-2025 Removed from agenda prior to committee meeting.
06-12-2025 Bill died when session adjourned *sine die*.

This bill seeks to amend the professional and occupational standards title, and more specifically the section relative to medical prescriptions and labels. The bill proposes to prohibit any healthcare professional licensing board from prohibiting or restricting the prescribing, administering, or dispensing for an off-label use of a drug that has been approved for a specific use by the federal FDA.

[HB 114](#) J. Domangue [R-53], Houma Health & Welfare
Provides for the use of artificial intelligence by healthcare providers. (08-01-2025)

03-25-2025 Prefiled and referred to committee.
04-29-2025 On agenda; voluntarily deferred prior to its consideration.
06-12-2025 Bill died when session adjourned *sine die*.

This bill seeks to amend the professional and occupational standards title, more specifically the introductory section applicable to all professions licensed under this title. The bill proposes to create a new section related to the use of artificial intelligence by healthcare professionals. The bill itemizes 6 permissible uses and 3 prohibited uses of artificial intelligence. The bill requires the state health department to promulgate rules to implement the new law, requires the state health department to investigate any actual, alleged, or suspected violations of the law, and authorizes the state health department to levy and collect a civil fine of \$10,000 per violation.

[HB 117](#) M. Echols [R-14], Monroe Labor & Industrial Relations
Provides for adoption of a medical fee reimbursement schedule for workers' compensation. (08-01-2025)

03-25-2025 Prefiled and referred to committee.
04-24-2025 Amended, then reported favorably.
04-28-2025 Engrossed; passed to 3rd reading and House floor vote.
05-05-2025 Passed House (62-26); sent to the Senate.
05-06-2025 Received in the Senate; committee referral pending.
05-07-2025 Referred to the Senate Committee on Labor & Industrial

Relations.

05-21-2025 Committee took no action; bill remains on committee agenda.
06-12-2025 Bill died when session adjourned *sine die*.

This bill seeks to amend the worker compensation law, and more specifically the process by which the office of worker compensation adjusts the medical fee reimbursement schedule. Instead of using the mean of usual and customary charges for services, treatments, drugs and supplies, the bill requires the state's reimbursement to be reasonable when compared to states surrounding Louisiana. The bill requires the office to collect data and information necessary to support annual adjustments to the fee schedule, and further, requires quarterly reporting to the appropriate legislative oversight committee. [House Committee Amendment No. 1472](#) made a technical clarification relative to the requirement for rates to be comparable to other states.

[HB 138](#) J. DeWitt [R-25], Tioga Health & Welfare
Provides with respect to the Louisiana State Board of Medical Examiners. (08-01-2025 gov. sig.)

03-26-2025 Prefiled and referred to committee.
05-07-2025 Removed from agenda prior to committee meeting.
05-14-2025 Amended, then reported favorably.
05-15-2025 Engrossed; passed to 3rd reading and House floor vote.
05-20-2025 Called for debate; returned to the calendar; notice given.
05-21-2025 Called for debate; returned to the calendar; notice given.
05-22-2025 Amended, then passed House (89-2); reengrossed;
Sent to the Senate.
05-27-2025 Received in the Senate; committee referral pending.
05-28-2025 Referred to the Senate Committee on Health & Welfare.
06-04-2025 Amended, then reported favorably;
Referred to Legislative Bureau;
Reported without Legislative Bureau amendments;
Passed to 3rd reading and final passage.
06-08-2025 Called for debate; returned to the calendar, subject to call.
06-09-2025 Amended, then passed Senate (39-0); returned to the House.
06-10-2025 House rejected Senate amendments (99-1);
Referred to Conference Committee;
Senate conferees appointed: Jackson-Andrews, McMath,
Pressly.
06-11-2025 House conferees appointed: Dewitt, Miller, LaCombe.
06-12-2025 Bill died when session adjourned *sine die*.

This bill seeks to amend the medical practice act, more specifically the membership of the now 10-member board and terms of its members. The bill seeks to add one new member to be selected from a list supplied by the Louisiana Academy of Physician Assistants, and further, seeks to change the current limit on the number of consecutive 4-year terms, from three to two. [House Committee Amendment No. 2127](#) removes most of the bill text and inserts some substantive changes. The requirement for various organizations to nominate members to the board is removed and replaced with a requirement for 11 members to be appointed by the governor, one physician from each of the state health department's nine administrative regions as well as one non-

physician provider licensed by the board. The consumer member will be removed. The requirement for minimum residence in the state at the time of appointment is changed from six months to five years. The members will serve at the pleasure of the governor. Finally, the effective date was changed to coincide with the date of the governor's signature. [House Floor Amendment No. 3407](#) reinstated the current sources of nominations for members and the duration of their terms but inserted a requirement for the members nominated to practice in specific congressional districts throughout the state. The amendment also retained the addition of the physician assistant seat provided in the original bill. [Senate Committee Amendment No. 2846](#) corrected a drafting error in the House floor amendment relative to specific congressional districts; changed the specific seat assignment of physician assistant to a 'non-physician healthcare professional whose profession is regulated by the board'; changed the duration of the term to four years for physician and consumer members and two years for non-physician members; and specified that first non-physician member appointed shall be a physician assistant. [Senate Floor Amendment No. 3109](#) restructured the board membership to 11 members: nine physicians (one from each congressional district), one consumer member and one non-physician provider regulated by the board. Further, the requirement for state residency at the time of appointment was increased to five years. The duration of the member terms was changed such that all existing members appointed prior to July 31, 2025 shall serve at the pleasure of the governor and new members appointed after August 1, 2025 shall serve four year terms and no more than three consecutive terms. Finally, the existing requirement for the executive director to be a licensed physician was changed to a permissive requirement.

HB 176	G. Firment [R-22], Pollock	Administration of Criminal Justice
Provides relative to regulation of certain hallucinogenic chemicals. (08-01-2025)		
03-31-2025	Prefiled and referred to committee.	
04-29-2025	Amended, then reported favorably.	
04-30-2025	Engrossed; passed to 3 rd reading and House floor vote.	
05-07-2025	Passed House (99-0); sent to the Senate; Received in the Senate; committee referral pending.	
05-08-2025	Referred to the Senate Committee on the Judiciary-C.	
05-20-2025	Reported favorably.	
05-21-2025	Referred to Legislative Bureau.	
05-27-2025	Reported without Legislative Bureau amendments; Passed to 3 rd reading and final passage.	
05-29-2025	Passed Senate (37-0); returned to the House; Received in the House without Senate amendments.	
06-02-2025	Enrolled; signed by House Speaker & Senate President.	
06-03-2025	Sent to the Governor.	
06-08-2025	Signed by Governor as Act No. 154 ; effective 08-01-2025.	

This bill amended the controlled substance law by creating a new section relative to certain hallucinogenic chemicals, namely (1) beta-phenyl-GABA {aka Phenibut, Anvifen}, (2) muscimol {derived from ibotenic acid and found in certain mushrooms}, and (3) ibotenic acid {found in Amanita muscaria mushrooms}. The bill criminalizes the production, manufacture, distribution, or possession with intent to produce, manufacture, or distribute any material, compound, mixture, preparation, or product intended for human consumption which contains any of the named chemicals or any

analog thereof. The bill established criminal penalties including fines and incarceration. The bill also criminalizes the simple possession of any substance containing the named chemicals and set the criminal penalties including fines and incarceration. [House Committee Amendment No. 1717](#) made technical corrections.

[HB 210](#) T. Chassion [D-44], Lafayette Health & Welfare
Provides relative to retention and archiving records in the state prescription monitoring program. (08-01-2025)

04-01-2025 Prefiled and referred to committee.
04-16-2025 Amended, then reported favorably.
04-22-2025 Engrossed; passed to 3rd reading and House floor vote.
04-24-2025 Passed House (94-0); sent to the Senate.
04-28-2025 Received in the Senate; committee referral pending.
04-29-2025 Referred to Senate Committee on Health & Welfare.
05-21-2025 Reported favorably.
05-27-2025 Referred to Legislative Bureau.
05-28-2025 Reported without Legislative Bureau amendments;
 Passed to 3rd reading and final passage.
05-29-2025 Called for debate; returned to the calendar, subject to call.
06-03-2025 Called for debate; passed Senate (38-0); returned to the House.
06-04-2025 Enrolled; signed by House Speaker & Senate President.
06-05-2025 Sent to the Governor.
06-08-2025 Signed by Governor as **[Act No. 159](#)**; effective 08-01-2025.

Sponsored by the La. Board of Pharmacy, this bill amended the prescription monitoring program (PMP) law, more specifically the existing section relative to retention and archiving PMP information. The bill added audit trail information to that section of law. [House Committee Amendment No. 1247](#) added a new section requiring the approval of the state archivist prior to destruction of any PMP information or audit trail information.

[HB 253](#) C. Boyer [R-46], Breaux Bridge Health & Welfare
Provides relative to kratom. (08-01-2025)

04-01-2025 Prefiled and referred to committee.
04-16-2025 Amended, then reported favorably.
04-22-2025 Engrossed; recommitted to the House Committee on
 Appropriations.
06-12-2025 Bill died when session adjourned *sine die*.

This bill seeks to amend the alcoholic beverage law by adding a new chapter relative to kratom products. The bill establishes a regulatory framework to be administered by the state health department. The bill establishes product and labeling standards for kratom products, which are defined in the bill as food or dietary supplements containing kratom or kratom leaf extracts. The bill contains registration and reporting requirements and prohibits sales or transfers of such products to any person under the age of 21 years. [House Committee Amendment No. 1143](#) made technical changes to the vendor definition and registration requirement. Since the fiscal note estimates expenses greater than \$100,000, this bill was dual referred to the House Committee on Appropriations prior to any House floor vote.

Provides for the utilization of pharmaceutical rebates by pharmacy benefit managers.

~~(08-01-2025 gov. sig.)~~

04-01-2025 Prefiled and referred to committee.
04-29-2025 Voluntarily deferred for one week.
05-07-2025 Considered and then deferred for one week.
05-14-2025 Amended, then reported favorably.
05-15-2025 Engrossed; recommitted to the House Committee on House & Governmental Affairs.
05-20-2025 Amended, then reported favorably.
05-21-2025 Reengrossed; passed to 3rd reading and House floor vote.
05-22-2025 Passed House (86-0); sent to the Senate.
05-27-2025 Received in the Senate; committee referral pending.
05-28-2025 Referred to the Senate Committee on Insurance.
06-04-2025 Amended, then reported favorably;
Referred to Legislative Bureau;
Reported without Legislative Bureau amendments;
Passed to 3rd reading and final passage.
06-08-2025 Amended, then returned to the calendar, subject to call.
06-09-2025 Passed Senate (38-0); returned to the House;
Received in the House with Senate amendments.
06-10-2025 Called for debate; returned to the calendar; notice given.
06-11-2025 Called for debate; returned to the calendar; notice given.
06-12-2025 House concurred with Senate amendments (100-0);
Enrolled; signed by House Speaker & Senate President.
06-13-2025 Sent to the Governor.
06-20-2025 Signed by Governor as **Act No. 474**; effective 06-20-2025.

This bill amended the insurance law, more specifically the existing section relative to pharmacy benefit managers (PBM). The original bill required the PBM to calculate the patient's cost-share for each prescription drug at the point of sale based on a price that is reduced by at least 100% of all rebates received, or to be received, in connection with dispensing or administering the drug. Further, the cost savings of any rebate exceeding the patient's cost-share shall be passed on to the sponsor of the health plan. [House Committee Amendment No. 2789](#) removes the bill text and replaces it with new text. The new text redefined the term "rebate", and further, authorizes the commissioner of the state insurance department to audit PBM books and records to determine the accuracy of the annual transparency report. Moreover, the commissioner may review and approve PBM contracts to ensure fair reimbursement amounts; however, such contracts shall be exempted from the state public records law. Since the committee amendment added new provisions to the state public records law, the bill was dually-referred to the House Committee on House & Governmental Affairs which has jurisdiction over that law. [House Committee Amendment No. 3153](#) corrected a drafting error in the assignment of confidentiality to certain PBM records. [Senate Committee Amendment No. 2863](#) removed the entire contents of the bill except for the public record law amendment and then inserted substantive changes to the existing law relative to PBMs relative to maximum allowable costs, rebates, effective rate pricing, use of National Average Drug Acquisition Costs (NADAC) for pharmacy reimbursements, commissioner review of compensation program to ensure fair

pharmacy reimbursement, and audits of PBM transparency reports. The amendment modified the existing PBM law in Title 40, more specifically the provisions relative to the Pharmacy Benefit Manager Monitoring Advisory Council and its membership. The 25 member council was reduced to 13 members and transferred to the state insurance department. The amendment also modified the unfair trade practices of that PBM law by prohibiting effective rate pricing in addition to spread pricing as well as expanding the patient steering prohibition. The amendment also inserted a new section in the state insurance law, more specifically in the part relative to PBMs. The new section permits a PBM to negotiate rebates from drug manufacturers but prohibits them from retaining such rebates and requires them to pass such rebates to plan sponsors. A new provision was added to make most of the bill effective upon the governor's signature but delayed until January 2027 the enforcement of the prohibition on effective rate pricing. [Senate Floor Amendment No. 2984](#) modified some of the previous Senate committee amendments, some technical and some substantive, including the establishment of a state fund to contain any funds arising from enforcement actions against PBMs by the attorney general or insurance commissioner.

HB 358	D. Miller [D-40], Opelousas	Health & Welfare
Permits a pharmacy technician to work remotely in certain circumstances. (08-01-2025)		
04-03-2025	Prefiled and referred to committee.	
04-23-2025	Reported favorably.	
04-24-2024	Engrossed; passed to 3 rd reading and House floor vote.	
04-29-2025	Passed House (95-0); sent to the Senate; Received in the Senate; committee referral pending.	
04-30-2025	Referred to Senate Committee on Health & Welfare.	
05-14-2025	Amended, then reported favorably.	
05-19-2025	Referred to the Legislative Bureau.	
05-20-2025	Reported without Legislative Bureau amendments; Passed to 3 rd reading and final passage.	
05-27-2025	Passed Senate (37-0); returned to the House; Received in the House with Senate amendments.	
05-29-2025	Called for debate; returned to the calendar; notice given.	
06-02-2025	House rejected Senate amendments; Referred to Conference Committee; House conferees appointed: Miller, Turner, Echols.	
06-09-2025	Senate conferees appointed: McMath, Boudreaux, Cloud.	
06-10-2025	Senate conferee changed: Jackson-Andrews vice McMath.	
06-11-2025	House adopted Conference Committee Report (88-4).	
06-12-2025	Bill died when session adjourned <i>sine die</i> .	

This bill seeks to amend the pharmacy practice law, more specifically the existing section relative to pharmacy technicians. The bill proposes to add a new subsection authorizing pharmacy technicians who are licensed by the La. Board of Pharmacy and who are employed by or contracted with an in-state pharmacy to remotely access electronic prescription records in the pharmacy software system or dispensing information system. The bill requires the pharmacy to establish controls to protect the privacy and security of confidential records, and prohibits the duplication, downloading or removal of a pharmacy's information system or dispensing information system. [Senate Committee Amendment No. 1561](#) clarified that remote access may occur from

any location other than a pharmacy; and further, directed the Board of Pharmacy to promulgate rules to implement this new subsection. [Conference Committee Report No. 3812](#) would prohibit the pharmacy board from issuing or renewing a pharmacy permit for a pharmacy wholly or partially owned or controlled by a PBM or its subsidiary effective January 1, 2027.

[HB 377](#) C. Owen [R-30], Rosepine Health & Welfare
Authorizes an individual to refuse certain medical treatments. (08-01-2025)
04-03-2025 Prefiled and referred to committee.
05-07-2025 On agenda, but not considered.
05-14-2025 Amended, then reported favorably by substitute.
05-15-2025 Became HB 690. **See HB 690 for further information.**

This bill seeks to amend the healthcare consumer law by creating a new subpart authorizing an individual to refuse emergency use authorization (EUA) drugs, devices, tests and procedures. The bill requires a healthcare professional, clinic, hospital or other entity administering an EUA drug to give prior notice to the patient and receive their written informed consent, or in the alternative their documented refusal. The bill specifies the content of the prior notice and other procedural safeguards. House Committee Amendment No. 2856 removed the bill text and inserted new text in a different section of law. The purpose of the new text is to direct the state surgeon general to promulgate rules for all healthcare providers relative to Emergency Use Authorization (EUA) medical activities.

[HB 423](#) J. LaCombe [R-18], Livonia Health & Welfare
Provides relative to healthcare providers displaying evidence of proper licensure in advertising. (08-01-2025)
04-03-2025 Prefiled and referred to committee.
05-08-2025 Amended, then reported favorably.
05-12-2025 Engrossed; passed to 3rd reading and House floor vote.
05-14-2025 Called for debate; returned to the calendar; notice given.
05-19-2025 Passed House (98-0); sent to the Senate;
Received in the Senate; committee referral pending.
05-20-2025 Referred to the Senate Committee on Health & Welfare.
05-28-2025 Removed from agenda prior to meeting.
06-08-2025 Amended, then reported favorably;
Referred to Legislative Bureau;
Reported without Legislative Bureau amendments;
Passed to 3rd reading and final passage.
06-09-2025 Amended, then passed Senate (38-0); returned to the House;
Received in the House with Senate amendments.
06-10-2025 House concurred with Senate amendments ((95-0).
06-11-2025 Enrolled; signed by House Speaker & Senate President;
Sent to the Governor.
06-20-2025 Signed by Governor as **[Act No. 362](#)**; effective 08-01-2025.

This bill amended two different titles of law – the professional and occupational standards in Title 37 as well as the trade and commerce law in Title 51. Within the existing section relative to identification of healthcare providers in the professional and

occupational standards, the bill sought to require healthcare providers demonstrate evidence of proper licensure in any advertisements in print, electronic, or social media. Within the trade and commerce law, the bill amended an existing restriction on the use of the title “Doctor” or “Dr.” to permit the licensing board of the provider violating that law to discipline that provider. [House Committee Amendment No. 2482](#) amended the bill to clarify the requirement applies to licensed healthcare professionals while providing healthcare and not organizational providers. [Senate Committee Amendment No. 3083](#) inserted an amendment to the state insurance law relative to denial of prescription drug coverage for an opioid prescription in certain circumstances, and also made minor modifications of the provider identification requirement in advertisements. [Senate Floor Amendment No. 3164](#) removed all of the original text relative to professional and occupational standards, retaining the original text relative to trade and commerce laws as well as the insurance law amendment.

[HB 575](#) L. Ventrella [R-65], Greenwell Springs Civil Law & Procedure
Provides relative to liability for the unlawful termination of a pregnancy. (08-01-2025)

04-04-2025	Prefiled and referred to committee.
05-12-2025	Amended, then reported favorably (8-2-1).
05-13-2025	Engrossed; passed to 3 rd reading and House floor vote.
05-14-2025	Amended, then passed House (59-25); reengrossed; Sent to the Senate.
05-19-2025	Received in the Senate; committee referral pending.
05-20-2025	Referred to the Senate Committee on Judiciary-A.
05-28-2025	Amended, then reported favorably (3-2).
06-01-2025	Referred to Legislative Bureau; Reported without Legislative Bureau amendments; Passed to 3 rd reading and final passage.
06-03-2025	Called for debate; returned to the calendar, subject to call.
06-08-2025	Amended, then passed Senate (28-9); returned to the House; Received in the House with Senate amendments.
06-10-2025	House concurred with Senate amendments (77-19).
06-11-2025	Enrolled; signed by House Speaker & Senate President.
06-12-2025	Sent to the Governor.
06-20-2025	Signed by Governor as <u>Act No. 383</u> ; effective 08-01-2025.

This bill amended the state civil code to create a cause of action for the unlawful termination of a pregnancy. Any person who performs, causes, aids or abets an abortion, including by manufacturing, administering, prescribing, dispensing, distributing or selling an abortion-inducing drug shall be liable to the mother of the unborn child as well as certain family members, regardless of whether the abortion resulted in the death of the unborn child. The bill increases the duration of the time period within which an action may be brought, from 3 years to 5 years after the date of the abortion. In addition, the bill permits the award of statutory, special, general and exemplary damages. The bill stipulates the medical malpractice law and limitation of liability contained in that law shall not be applicable to this action. The bill prohibits the initiation of action against (1) the woman upon whom the abortion was performed, caused or attempted; (2) a healthcare provider licensed in this state for the provision of healthcare that is not defined as abortion; and (3) a pharmacist or pharmacy licensed in this state for actions related to filling a prescription for a drug, medicine or other substance

prescribed for a bona fide medical reason. [House Committee Amendment No. 2655](#) expands the scope of liability by (1) adding entities to persons, and (2) replacing the “aids and abets” language with “substantially facilitates” which is defined as manufacturing, administering, prescribing, dispensing, distributing, marketing, advertising, promoting, or selling an abortion-inducing drug. The amendment also adds an additional exclusion from liability for mental health professionals who provide counseling in a manner that does not include the promotion of or referral to abortion resources. [House Floor Amendment No. 2921](#) removed manufacturing from the definition of the term “substantially facilitates.” [House Floor Amendment No. 1625](#) made a technical correction. [Senate Committee Amendment No. 2301](#) made several clarifications: (1) limits the range of persons who may bring an action to the mother of the unborn child as well as the biological father of the unborn child, but the father is excluded if he impregnated the mother by rape, sexual assault or incest; (2) the term “substantially facilitates” was redefined to mean “administering, prescribing, dispensing, or selling, or coordinating the sale of an abortion-inducing drug to a person in this state, and shall NOT include the administering, prescribing, dispensing, distributing, selling, or coordinating the sale of medications for legal, therapeutic purposes under the laws of this state”; (3) The provision which eliminated the applicability of medical malpractice and liability limitations within that law were amended to add a rebuttable presumption that the medical malpractice act applies to any covered health care provider licensed to practice in this state and practicing within the lawful scope of practice in accordance with the law. [Senate Floor Amendment No. 2635](#) made a technical change. [Senate Floor Amendment No. 3036](#) made several clarifications of previous amendments. [Senate Floor Amendment No. 3099](#) removed mental health professionals and advocates for sexual assault survivors from the list of healthcare providers immune to actions for damages authorized by this bill.

<u>HB 606</u>	C. Turner [R-12], Ruston	Ways & Means
Exempts prescription drugs and insulin from local sales and use taxes. (08-01-2025)		
04-04-2025	Prefiled and referred to committee.	
05-06-2025	On agenda, but not considered.	
05-13-2025	Reported favorably (9-5).	
05-14-2025	Engrossed; passed to 3 rd reading and House floor vote.	
05-19-2025	Caled for debate; returned to the calendar, subject to call.	
06-12-2025	Bill died when session adjourned <i>sine die</i> .	

This bill seeks to amend the revenue and taxation law, to add prescription drugs as well as prescription and nonprescription insulin to the list of items exempted from local sales and use taxes.

<u>HB 690</u>	C. Owen [R-30], Rosepine	Substituted for HB 377
Directs the Surgeon General to draft and promulgate rules for the administration of medical activities under Emergency Use Authorization (EUA) for all members of the healthcare community in Louisiana. (gov. sig.)		
05-15-2025	Reported as a substitute for HB 377 by the House Committee on Health & Welfare.	
05-19-2025	Engrossed; passed to 3 rd reading and House floor vote.	
05-20-2025	Amended, then passed House (73-22); reengrossed; Sent to the Senate.	

05-21-2025 Received in the Senate; committee referral pending.
 05-27-2025 Referred to the Senate Committee on Health & Welfare.
 06-04-2025 Amended, then reported favorably;
 Referred to Legislative Bureau;
 Reported without Legislative Bureau amendments;
 Passed to 3rd reading and final passage.
 06-08-2025 Amended, then returned to the calendar, subject to call.
 06-09-2025 Passed Senate (39-0); returned to the House;
 Received in the House with Senate amendments.
 06-10-2025 House rejected Senate amendments (57-37);
 Referred to Conference Committee;
 Senate conferees appointed: Fesi, Cloud, McMath.
 06-11-2025 House conferees appointed: Owen, Miller, Crews.
 06-12-2025 House adopted Conference Committee Report (96-0);
 Senate adopted Conference Committee Report (37-0);
 Enrolled; signed by House Speaker & Senate President.
 06-16-2025 Sent to the Governor.
 06-20-2025 Signed by Governor as **Act No. 396**; effective 06-20-2025.

This bill amended the public health law, more specifically the authority of the state surgeon general. The new section of law directs the state surgeon general to promulgate rules for medical activities under Emergency Use Authorization (EUA). The rules shall be applicable to all healthcare providers in the state including pharmacies and other healthcare facilities. The rules shall not supersede federal EUA requirements but shall complement them with state-specific guidance. The bill itemizes the subject matter for such rules, including procedure for safe and effective administration of EUA-authorized medical products, guidelines for informed consent, protocols for monitoring and reporting adverse events, standards for training and education of healthcare providers on proper use of EUA-authorized products, measures to ensure access to EUA-authorized products and protections, provisions for transparency, including public disclosure of EUA-related activities by healthcare entities, and procedures for compliance and enforcement. [House Floor Amendment No. 1831](#) corrected a typographical error. [Senate Committee Amendment No. 2834](#) made a technical change. [Senate Floor Amendment No. 2961](#) changed the requirement to promulgate rules on the enumerated topics subject to administrative procedure act requirements to the development of protocols on the enumerated topics subject to review and approval by the House and Senate Committees on Health & Welfare. [Senate Floor Amendment No. 3063](#) inserted a provision for the surgeon general to coordinate with several named agencies and organizations during the development of the protocols. [Senate Floor Amendment No. 3123](#) made some technical corrections. [Conference Committee Report No. 4377](#) adopted the Senate Committee Amendments and two of the Senate Floor Amendments (3063 and 3123) but rejected Senate Floor Amendment No. 2961.

House Resolutions

[HR 329](#) D. Miller [D-40], Opelousas
 Urges the attorney general and the Louisiana Department of Insurance to investigate pharmacy benefit managers (PBMs) for potential violations of law and to urge and request the legislature to pass legislation prohibiting PBMs from owning or having a

financial interest in pharmacies in this state.

- 06-08-2025 Filed; procedural rules suspended; passed to 3rd reading and House floor vote.
- 06-10-2025 Passed House (92-0); enrolled; signed by House Speaker.
- 06-11-2025 Delivered to the Secretary of State.

House Concurrent Resolutions

[HCR 73](#) C. Turner [R-12], Ruston Health & Welfare
Memorializes the United States Congress to take action relative to the use of pharmacy benefit managers and their impact on the citizens of this state.

- 05-27-2025 Introduced; committee referral pending.
- 05-28-2025 Referred to the House Committee on Health & Welfare.
- 06-03-2025 Reported favorably.
- 06-04-2025 Engrossed; passed to 3rd reading and House floor vote.
- 06-08-2024 Passed House (91-0); sent to the Senate;
Received in the Senate; committee referral pending.
- 06-09-2025 Procedural rule suspended; passed Senate (39-0);
Returned to the House; received without Senate amendments.
- 06-10-2025 Enrolled; signed by House Speaker & Senate President.
- 06-11-2025 Delivered to the Secretary of State.

[19]

Senate

Bills

[SB 19](#) M. Fesi [R-20], Houma Health & Welfare
Provides relative to the dispensing of ivermectin. (~~08-01-2025~~ gov. sig.)

- 03-24-2025 Prefiled and referred to committee.
- 04-23-2025 Amended, then reported favorably (6-3).
- 04-29-2025 Engrossed; passed to 3rd reading and Senate floor vote.
- 04-30-2025 Passed Senate (28-8); sent to the House.
- 05-05-2025 Received in the House; committee referral pending.
- 05-06-2025 Referred to the House Committee on Health & Welfare.
- 05-21-2025 On agenda; not considered.
- 05-28-2025 Amended, then reported favorably (10-1);
Referred to Legislative Bureau.
- 05-29-2025 Reported without Legislative Bureau amendments.
- 06-02-2025 Passed to 3rd reading and final passage.
- 06-03-2025 Passed House (67-26); returned to the Senate.
- 06-04-2025 Received in the Senate with House amendments.
- 06-09-2025 Senate concurred with House amendments (31-4).
- 06-10-2025 Enrolled; signed by Senate President & House Speaker.
- 06-11-2025 Sent to the Governor.
- 06-20-2025 Signed by Governor as **Act No. 464**; effective 06-20-2025.

This bill amended the pharmacy practice act by creating a new section authorizing

pharmacists to dispense ivermectin to any person 18 years of age or older pursuant to a standing order issued by the state health department. The bill requires the department to promulgate rules to implement the new law, provides immunity from disciplinary or other adverse administrative action by the state board of pharmacy as well as immunity from civil liability in the absence of gross negligence or willful misconduct, and clearly indicates nothing in the new law requires insurance coverage of ivermectin prescriptions. [Senate Committee Amendment No. 699](#) added a provision to make the new law effective upon the governor's signature. [House Committee Amendment No. 3604](#) made two technical corrections and also changed the issuer of the standing order from the state health department itself to a healthcare provider with prescriptive authority within the state health department.

<u>SB 78</u>	B. Myers [R-23], Lafayette	Judiciary-C
Provides relative to drug paraphernalia. (<i>gov. sig.</i>)		
04-02-2025	Prefiled and referred to committee.	
04-15-2025	Amended, then reported favorably.	
04-16-2024	Engrossed; passed to 3 rd reading and Senate floor vote.	
04-22-2025	Amended, then passed Senate (37-0); reengrossed; sent to the House.	
04-23-2025	Received in the House; committee referral pending.	
04-24-2025	Referred to House Committee on Administration of Criminal Justice.	
05-20-2025	Reported favorably; referred to the Legislative Bureau.	
05-21-2025	Reported without Legislative Bureau amendments.	
05-22-2025	Passed to 3 rd reading and final passage.	
06-02-2025	Amended, then passed House (97-0); returned to the Senate; Received in the Senate with House amendments.	
06-03-2025	Senate concurred with House amendments (37-0).	
06-04-2025	Enrolled; signed by Senate President & House Speaker.	
06-05-2025	Sent to the Governor.	
06-08-2025	Signed by Governor as <u>Act No. 102</u> ; effective 06-08-2025.	

This bill amended the controlled substance law, more specifically the section related to drug paraphernalia. The previous law exempted from the definition of drug paraphernalia rapid fentanyl test strips or other equipment or devices used solely to detect fentanyl or its analogues. The bill retained rapid fentanyl test strips and changed “fentanyl or its analogues” to “any controlled substance, chemical or compound that can cause physical harm or death.” [Senate Committee Amendment No. 494](#) made a technical clarification. [Senate Floor Amendment No. 740](#) itemized additional testing devices to be excluded from the definition of drug paraphernalia. [House Floor Amendment No. 3355](#) simplified the text of the proposed exclusion from the definition of drug paraphernalia, to exclude any testing device or equipment that could detect any controlled substance, chemical or compound that can cause physical harm or death provided that such device or equipment is not used to facilitate manufacturing or distribution of any controlled substance.

<u>SB 98</u>	B. Myers [R-23], Lafayette	Judiciary-C
Increases the penalties for the retail sale of nitrous oxide. (08-01-2025)		
04-03-2025	Prefiled and referred to committee.	

04-15-2025 Amended, then reported favorably.
 04-16-2024 Engrossed; passed to 3rd reading and Senate floor vote.
 04-22-2025 Amended, then passed Senate (37-0); reengrossed; sent to the House.
 04-23-2025 Received in the House; committee referral pending.
 04-24-2025 Referred to House Committee on Administration of Criminal Justice.
 05-20-2025 Reported favorably; referred to the Legislative Bureau.
 05-21-2025 Reported without Legislative Bureau amendments.
 05-22-2025 Passed to 3rd reading and final passage.
 06-02-2025 Amended, then passed House (96-0); returned to the Senate; Received in the Senate with House amendments.
 06-03-2025 Senate concurred with House amendments (37-0).
 06-04-2025 Enrolled; signed by Senate President & House Speaker.
 06-05-2025 Sent to the Governor.
 06-08-2025 Signed by Governor as **Act No. 106**; effective 08-01-2025.

This bill amended the controlled substance law, more specifically the existing section relative to improper sale and possession of certain dangerous chemical substances including nitrous oxide. In addition to the existing criminal penalties for improper possession, inhalation, ingestion, or use of the specified chemicals, the bill added new criminal penalties for the production, manufacture, possession, purchase, sale or other transfer of the specified chemicals by any person or business. Further, in the event any business who violates this law holds a permit from the office of alcohol and tobacco control shall have its permit suspended or revoked. [Senate Committee Amendment No. 473](#) added a clarification that businesses include on-line retailers. [Senate Floor Amendment No. 607](#) clarified the age limit in the exclusion relative to prescribed medical uses applies to the patient instead of the prescriber. [Senate Floor Amendment No. 731](#) made technical changes in the exclusion relative to the use of nitrous oxide in food preparation. [Senate Floor Amendment No. 735](#) made additional technical changes to that same section. [House Floor Amendment No. 3856](#) corrected a formatting error from a previous amendment.

SB 134 T. Pressly [R-38], Shreveport Health & Welfare
 Provides relative to health care definitions. (08-01-2025)

04-04-2025 Prefiled and referred to committee.
 04-23-2025 Reported favorably.
 04-29-2025 Engrossed; passed to 3rd reading and Senate floor vote.
 04-30-2025 Amended, then passed Senate (26-11); reengrossed; Sent to the House.
 05-05-2025 Received in the House; committee referral pending.
 05-06-2025 Referred to the House Committee on Health & Welfare.
 05-21-2025 Reported favorably; referred to Legislative Bureau.
 05-22-2025 Reported without Legislative Bureau amendments.
 05-27-2025 Passed to 3rd reading and final passage.
 06-02-2025 During debate, returned to the calendar; notice given.
 06-03-2025 Passed House (58-37); returned to the Senate; Received in the Senate without House amendments.
 06-04-2025 Enrolled; signed by Senate President & House Speaker.

06-05-2025 Sent to the Governor.
06-11-2025 Became **Act No. 342** without Governor's signature;
effective 08-01-2025

This bill amended some key definitions in two portions of the public health law. With respect to the section of law for advance directives, the bill amended the definition of "healthcare provider" to add any entity listed in the definition of the same term in the medical malpractice law. The bill also amended the definition of "healthcare provider" and "malpractice" in the medical malpractice law. The provider definition added some specific healthcare disciplines as well as administrators. The malpractice definition added management firms and administrative personnel. [Senate Floor Amendment No. 1148](#) removed managerial and supportive personnel but retained administrative personnel and also removed physical therapist assistants and occupational therapists from the medical malpractice law {however, the law covers all licensed or registered healthcare providers, so they are still included but not specifically listed}. [Senate Floor Amendment No. 1154](#) made a technical clarification of Senate Floor Amendment No. 1148.

SB 154 J. Morris [R-35], West Monroe Judiciary-C
Criminalizes the possession or distribution of kratom. (08-01-2025)
04-04-2025 Prefiled and referred to committee.
04-29-2025 Amended, then reported favorably.
04-30-2025 Engrossed; passed to 3rd reading and Senate floor vote.
05-06-2025 Passed Senate (26-11); sent to the House;
Received in the House; committee referral pending.
05-07-2025 Referred to the House Committee on Administration of
Criminal Justice.
05-14-2025 Reported favorably (10-1); referred to Legislative Bureau.
05-15-2025 Reported without Legislative Bureau amendments.
05-19-2025 Passed to 3rd reading and final passage.
05-27-2025 Passed House (86-6); returned to the Senate;
Received in the Senate without House amendment.
05-28-2025 Enrolled; signed by Senate President & House Speaker.
05-29-2025 Sent to the Governor.
06-04-2025 Signed by Governor as **Act No. 41**; effective 08-01-2025.

*This bill amended the controlled substance law, more specifically the state schedule of controlled substances. The bill added *Mitragyna speciosa* {aka kratom} to Schedule I and also added a new section relative to the unlawful possession, production or distribution of kratom. The bill also repealed the existing section related to the unlawful distribution of kratom to minors. [Senate Committee Amendment No. 1018](#) amended the listing of *Mitragyna speciosa* in Schedule I, changing it to list both mitragynine and 7-hydroxymitragynine. In addition, the new section relative to the unlawful possession, production or distribution of kratom was amended by adding cascading penalties based on weight of product, for both distribution and possession. Finally, the existing section of law related to prohibited plants was amended to add *Mitragyna speciosa* to that list.*

SB 173 K. Jackson-Andrews [D-34], Monroe Insurance
Provides for reimbursement rates paid by pharmacy benefit managers. (08-01-2025)

04-04-2025 Prefiled and referred to committee.
 05-14-2025 Amended, then voluntarily deferred for one week.
 05-21-2025 Voluntarily deferred for one week.
 06-12-2025 Bill died when session adjourned *sine die*.

This bill seeks to amend the insurance law, more specifically the existing sections relative to reimbursements paid by pharmacy benefit managers (PBM) as well as appeals of such reimbursements by pharmacies. With respect to the existing requirement that a PBM reimburse a pharmacy or pharmacist no less than the acquisition cost, the bill proposes to define acquisition cost of a drug as the actual cost of the drug as reflected on a supplier invoice, and for the service, the dispensing fee paid by the state Medicaid program. With respect to the existing section for appeals by pharmacies, the bill proposes several procedural enhancements. [Senate Committee Amendment No. 1691](#) corrected an error in the citation of the law to be amended. [Senate Committee Amendment No. 1728](#) excluded the state office of group benefits from the provisions of the bill.

[SB 182](#) K. Talbot [R-10], River Ridge Health & Welfare
 Provides relative to Medicaid prior authorization during a declared emergency. (08-01-2025)

04-04-2025 Prefiled and referred to committee.
 04-23-2025 Reported favorably.
 04-28-2025 Engrossed; passed to 3rd reading and Senate floor vote.
 04-29-2025 Amended, then passed Senate (39-0); reengrossed;
 Sent to the House.
 04-30-2025 Received in the House; committee referral pending.
 05-05-2025 Referred to the House Committee on Health & Welfare.
 06-03-2025 Reported favorably; referred to Legislative Bureau.
 06-04-2025 Reported without Legislative Bureau amendments.
 06-08-2025 Passed to 3rd reading and final passage.
 06-09-2025 Passed House (94-0); returned to the Senate;
 Received in the Senate without House amendments.
 06-10-2025 Enrolled; signed by Senate President & House Speaker.
 06-11-2025 Sent to the Governor.
 06-20-2025 Signed by Governor as [Act No. 440](#); effective 08-01-2025.

This bill amended the medical assistance program law, more specifically the sections related to Medicaid managed care. The bill added a new section authorizing the state health department to suspend prior authorization requirements in the Medicaid program during a state of emergency declared by the governor, but only for continuity of care for oncology patients, to ensure the provision of medically necessary oncologic drugs, services, equipment, supplies and therapies provided to state residents, whether located within the state or evacuated to other states. [Senate Floor Amendment No. 989](#) expanded the language to include all healthcare services instead of limiting it to the care of oncology patients.

[SB 194](#) J. Harris [D-4], New Orleans Insurance
 Provides relative to pharmacy benefit managers. (gov. sig.)
 04-04-2025 Prefiled and referred to committee.

06-12-2025 Bill died when session adjourned *sine die*.

This bill seeks to amend the insurance law as well as the pharmacy benefit manager (PBM) law. With respect to the insurance law, the bill defines compensation for a PBM to exclude any negotiated rebate and is limited to fees for services provided to its client healthcare plans. The bill also prohibits spread pricing as well as effective rate pricing. Further, the bill requires the insurance commissioner to audit PBMs and their contracts and compensation. With respect to the PBM law the bill adds effective rate pricing to the list of actions constituting unfair trade practices subject to enforcement by the state attorney general.

SB 243 M. Reese [R-30], Leesville Revenue & Fiscal Affairs
Provides relative to the sales and use tax exemption for the sale of certain prescription drugs. (gov. sig.)

04-23-2025 Introduced in the Senate; committee referral pending.
04-28-2025 Referred to the Senate Committee on Revenue & Fiscal Affairs.
05-06-2025 Amended, then reported favorably.
05-07-2025 Engrossed; passed to 3rd reading and Senate floor vote.
05-08-2025 Passed Senate (31-0); sent to the House.
05-12-2025 Received in the House; committee referral pending.
05-13-2025 Referred to the House Committee on Ways & Means.
05-27-2025 Reported favorably (14-0); referred to Legislative Bureau.
05-28-2025 Reported without Legislative Bureau amendments.
05-29-2025 Passed to 3rd reading and final passage.
06-03-2025 Passed House (95-0); returned to the Senate.
06-08-2025 Received in the Senate without House amendments;
Enrolled; signed by Senate President & House Speaker.
06-09-2025 Sent to the Governor.
06-11-2025 Signed by Governor as **Act No. 339**; effective 06-11-2025.

This bill amended the revenue law for local jurisdictions, more specifically the section authorizing exemptions to the imposition of local sales and use taxes, for the purpose of exempting prescription drugs sold to persons enrolled in the Louisiana Children's Health Insurance Program (LaCHIP) or Louisiana Medicaid. Senate Committee Amendment No. 1218 made technical corrections.

Senate Resolutions

SR 209 K. Talbot [R-10], River Ridge
Requests the Louisiana Department of Health to study the impacts of a prohibition on PBM ownership of pharmacies.

06-12-2025 Filed; procedural rules suspended; passed Senate (38-0);
Enrolled; signed by Senate President;
Delivered to the Secretary of State.

[10]

Hygeia Solutions

PO Box 80626 ~ Baton Rouge, LA 70898 ~ www.hygeia.fyi

Public policy in pharmacy practice

2025 Louisiana Legislature – Regular Session

Status of Bills on Watch List

On agenda

Returned to calendar, subject to call

Deferred

Last update: 07-07-2025

HOUSE

Pending Referral

HB:

SB:

APP

HB: 253

HCR-5 / Mon-Tue

H&W

HB: 112, 114

HCR-5 / Wed-Thu

4-29

SB:

Floor:

HB: 606

5-19

SB:

SENATE

Pending Referral

SB:

HB:

INS

SB: 173, 194

Room A / Wed

5-21

HB:

LIR

SB:

Room C / Thu

HB: 117

5-21

Floor:

SB:

HB:

Substitutes: HB: 377 → 690

Concurrence: HB: 138

SB:

Conference: HB: 358

SB:

Passed:

Act # 154 139 121 159 233 474 362 383 396

HB: 176, 099, 015, 210, 012, 264, 423, 575, 690

SoS

SoS

HR: 329 HCR: 073

Act # 41 342 102 106 339 464 440

SB: 154, 134, 078, 098, 243, 019, 182

SoS

SR: 209